Positive Preliminary Results from AM-101 Study

Preliminary results from Auris Medical's phase IIB study show that the local treatment with AM-101 was very well tolerated, and in particular that it had no negative impact on hearing. Patients suffering from acute tinnitus with established cochlear origin who received AM-101 at 0.81 mg/ml showed a statistically significant reduction in tinnitus loudness, sleep impact and the THI-12 questionnaire score (p <0.05 or <0.01). Further information on the clinical trial and detailed outcomes shall be published in a scientific journal.